References
- Jemal A , SiegelR, XuJ, WardE. Cancer statistics, 2010. CA Cancer J. Clin.60(5) , 277–300 (2010).
- Aliperti LA , PredinaJD, VachaniA, SinghalS. Local and systemic recurrence is the Achilles heel of cancer surgery. Ann. Surg. Oncol.18(3) , 603–607 (2011).
- Ehrlich P . Ueber den jetzigen stand der karzinomforschung. Ned. Tijdschr. Geneeskd.5 , 273–290 (1909).
- Kim R . Cancer immunoediting: from immune surveillance to immune escape. In: Cancer Immunotherapy. GC Prendergast, EM Jaffee (Eds). Academic Press, CA, USA, 9–28 (2007).
- Dunn GP , BruceAT, IkedaH, OldLJ, SchreiberRD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol.3(11) , 991–998 (2002).
- Tucker ZC , LagunaBA, MoonE, SinghalS. Adjuvant immunotherapy for non-small cell lung cancer. Cancer Treat. Rev.38(6) , 650–661 (2012).
- Hirschowitz EA , YannelliJR. Immunotherapy for lung cancer. Proc. Am. Thorac. Soc.6(2) , 224–232 (2009).
- Judy BF , AlipertiLA, PredinaJD et al. Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery. Neoplasia 14(4) , 352–359 (2012).
- Predina JD , JudyB, AlipertiLA et al. Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models. Cancer Gene Ther. 18(12) , 871–883 (2011).
- Predina JD , KapoorV, JudyBF et al. Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness. J. Hematol. Oncol. 5(34), (2012).
- Rosenberg SA . Progress in human tumour immunology and immunotherapy. Nature411(6835) , 380–384 (2001).
- Kruklitis RJ , SinghalS, DelongP et al. Immuno-gene therapy with interferon-β before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. J. Thorac. Cardiovasc. Surg. 127(1) , 123–130 (2004).
- Haas AR , SunJ, VachaniA et al. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin. Cancer Res. 12(1) , 214–222 (2006).
- Ochsenbein AF , KlenermanP, KarrerU et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl Acad. Sci. USA 96(5) , 2233–2238 (1999).
- Teicher BA . Transforming growth factor-β and the immune response to malignant disease. Clin. Cancer Res.13(21) , 6247–6251 (2007).
- Lee KM , ChuangE, GriffinM et al. Molecular basis of T cell inactivation by CTLA-4. Science 282(5397) , 2263–2266 (1998).
- Sakaguchi S , MiyaraM, CostantinoCM, HaflerDA. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol.10(7) , 490–500 (2010).
- Mantovani A , SozzaniS, LocatiM, AllavenaP, SicaA. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol.23(11) , 549–555 (2002).
- Fridlender ZG , SunJ, KimS et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell 16(3) , 183–194 (2009).
- Gabrilovich DI , NagarajS. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol.9(3) , 162–174 (2009).
- Grinshtein N , BridleB, WanY, BramsonJL. Neoadjuvant vaccination provides superior protection against tumor relapse following surgery compared with adjuvant vaccination. Cancer Res.69(9) , 3979–3985 (2009).
- Sterman DH . Gene therapy for malignant pleural mesothelioma. Hematol. Oncol. Clin. N. Am.19(6) , 1147–1173, viii (2005).
- Sterman DH , HaasA, MoonE et al. A trial of intrapleural adenoviral-mediated Interferon-alpha2b gene transfer for malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 184(12) , 1395–1399 (2011).
- Crittenden MR , ThanarajasingamU, VileRG, GoughMJ. Intratumoral immunotherapy: using the tumour against itself. Immunology114(1) , 11–22 (2005).
- Predina JD , JudyB, KapoorV et al. Characterization of surgical models of postoperative tumor recurrence for preclinical adjuvant therapy assessment. Am. J. Transl. Res. 4(2) , 206–218 (2012).
- Park SK , BrodyJI, WallaceHA, BlakemoreWS. Immunosuppressive effect of surgery. Lancet1(7689) , 53–55 (1971).
- Predina JD , JudyB, FridlenderZG et al. A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation. Cancer Biol. Ther. 13(9) , 745–755 (2012).
- De Grand AM , FrangioniJV. An operational near-infrared fluorescence imaging system prototype for large animal surgery. Technol. Cancer Res. Treat.2(6) , 553–562 (2003).